Who Paid My Doc
Nintedanib in PF-ILD (extension)
Research payments
$103,785
Through program year 2024, $103,785 in research payments was reported against Nintedanib in PF-ILD (extension), across 1,235 payments.
- Paid by (largest first)
- Boehringer Ingelheim International GmbH; Boehringer Ingelheim Limited; Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $7,197 | 2 |
| 2021 | Research | $16,883 | 377 |
| 2020 | Research | $34,851 | 539 |
| 2019 | Research | $44,854 | 317 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Lake Morrison Durham, NC Named on 57 payments
- Lucas Pitts Kansas City, KS Named on 47 payments
- Sonye Danoff Baltimore, MD Named on 45 payments
- Tejaswini Kulkarni Birmingham, AL Named on 42 payments
- Rafael Martinez Tampa, FL Named on 42 payments
- Neil Ettinger Chesterfield, MO Named on 41 payments
- Danielle Antin-Ozerkis New Haven, CT Named on 38 payments
- Oksana Shlobin Falls Church, VA Named on 38 payments
- Stephen Samuel Weigt Los Angeles, CA Named on 37 payments
- Teng Moua Rochester, MN Named on 37 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.